Published online before print March 15, 2004, doi: 10.1161/01.CIR.0000124064.00494.21
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2004;109:1680-1685.)
© 2004 American Heart Association, Inc.
Basic Science Reports |
Brain Natriuretic Peptide Enhances Renal Actions of Furosemide and Suppresses Furosemide-Induced Aldosterone Activation in Experimental Heart Failure
From the Cardiorenal Research Laboratory, Department of Physiology and Internal Medicine, Mayo Clinic and Foundation, Rochester, Minn.
Correspondence to Alessandro Cataliotti, MD, Cardiorenal Research Laboratory, Mayo Clinic and Foundation, Rochester, MN 55905. E-mail cataliotti.alessandro{at}mayo.edu
Received March 5, 2003; de novo received September 29, 2003; revision received December 8, 2003; accepted December 10, 2003.
Background— The renal actions of brain natriuretic peptide (BNP) in congestive heart failure (CHF) are associated with increased diuresis and natriuresis, preserved glomerular filtration rate (GFR), and lack of activation of the renin-angiotensin-aldosterone system (RAAS). In contrast, diuretic-induced natriuresis may be associated with reduced GFR and RAAS activation. The objective of this study was to test the hypothesis that exogenous BNP enhances the renal diuretic and natriuretic actions of furosemide (Fs) and retards the activation of aldosterone in a model of CHF.
Methods and Results— CHF was produced in 2 groups of dogs by ventricular pacing. One group received continuous (90-minute) intravenous Fs (1 mg · kg–1 · h–1). A second group (Fs+BNP) received 45-minute intravenous coinfusion of Fs (1 mg · kg–1 · h–1) and low-dose (2 pmol · kg–1 · min–1) BNP followed by 45-minute coinfusion of Fs (1 mg · kg–1 · h–1) and high-dose (10 pmol · kg–1 · min–1) BNP. Fs increased urinary flow, but the effect of Fs+BNP was greater. Similarly, urinary sodium excretion was higher in the Fs+BNP group. Although GFR tended to decrease in the Fs group, it increased in the Fs+BNP group (35±3 to 56±4*) (* indicates P<0.05 versus baseline) (P<0.0001 between groups). Plasma aldosterone increased with Fs (41±10 to 100±11* ng/dL) but was attenuated in the Fs+BNP group (44±11 to 54±9 ng/dL low-dose and to 47±7 ng/dL high-dose) (P=0.0007 between groups).
Conclusions— Fs+BNP has more profound diuretic and natriuretic responses than Fs alone and also increases GFR without activation of aldosterone. Coadministration of BNP and loop diuretic is effective in maximizing natriuresis and diuresis while preserving renal function and inhibiting activation of aldosterone.
Key Words: diuretics • natriuretic peptide, brain • renin-angiotensin system • glomerular filtration rate
This article has been cited by other articles:
 |
|
 |
|
  H H Chen, F L Martin, R J Gibbons, J A Schirger, R S Wright, R M Schears, M M Redfield, R D Simari, A Lerman, A Cataliotti, et al. Low-dose nesiritide in human anterior myocardial infarction suppresses aldosterone and preserves ventricular function and structure: a proof of concept study Heart, August 15, 2009; 95(16): 1315 - 1319. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Y. W. Lee, H. H. Chen, O. Lisy, S. Swan, C. Cannon, H. D. Lieu, and J. C. Burnett Jr. Pharmacodynamics of a Novel Designer Natriuretic Peptide, CD-NP, in a First-in-Human Clinical Trial in Healthy Subjects J. Clin. Pharmacol., June 1, 2009; 49(6): 668 - 673. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Cataliotti, H. H. Chen, J. A. Schirger, F. L. Martin, G. Boerrigter, L. C. Costello-Boerrigter, K. D. James, K. Polowy, M. A. Miller, N. B. Malkar, et al. Chronic Actions of a Novel Oral B-Type Natriuretic Peptide Conjugate in Normal Dogs and Acute Actions in Angiotensin II-Mediated Hypertension Circulation, October 21, 2008; 118(17): 1729 - 1736. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Witteles, D. Kao, D. Christopherson, K. Matsuda, R. H. Vagelos, D. Schreiber, and M. B. Fowler Impact of Nesiritide on Renal Function in Patients With Acute Decompensated Heart Failure and Pre-Existing Renal Dysfunction: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial J. Am. Coll. Cardiol., November 6, 2007; 50(19): 1835 - 1840. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. L. Martin, T. Supaporn, H. H. Chen, S. M. Sandberg, Y. Matsuda, M. Jougasaki, and J. C. Burnett Jr. Distinct roles for renal particulate and soluble guanylyl cyclases in preserving renal function in experimental acute heart failure Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2007; 293(4): R1580 - R1585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Belluardo, A. Cataliotti, L. Bonaiuto, E. Giuffre, E. Maugeri, P. Noto, G. Orlando, G. Raspa, B. Piazza, L. Babuin, et al. Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1529 - H1535. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ahmed, A. Husain, T. E. Love, G. Gambassi, L. J. Dell'Italia, G. S. Francis, M. Gheorghiade, R. M. Allman, S. Meleth, and R. C. Bourge Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods Eur. Heart J., June 2, 2006; 27(12): 1431 - 1439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. W. Schrier Role of Diminished Renal Function in Cardiovascular Mortality: Marker or Pathogenetic Factor? J. Am. Coll. Cardiol., January 3, 2006; 47(1): 1 - 8. [Abstract] [Full Text]
|
|
|
|
 |
|
 Y. Kikumoto, J. Wada, and H. Makino The Application of Synthetic hANP in Diabetic Nephropathy With Nephrotic Syndrome Diabetes Care, January 1, 2006; 29(1): 172 - 173. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Onat, J. Stathopoulos, A. Rose, K. Newman, R. R Sciacca, U. P Jorde, and P. C Colombo Reliability of Nesiritide Infusion via Non-Primed Tubing and Heparin-Coated Catheters Ann. Pharmacother., October 1, 2005; 39(10): 1617 - 1619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Cataliotti, J. A. Schirger, F. L. Martin, H. H. Chen, P. M. McKie, G. Boerrigter, L. C. Costello-Boerrigter, G. Harty, D. M. Heublein, S. M. Sandberg, et al. Oral Human Brain Natriuretic Peptide Activates Cyclic Guanosine 3',5'-Monophosphate and Decreases Mean Arterial Pressure Circulation, August 9, 2005; 112(6): 836 - 840. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Elkayam, D. J. Wang, T. C. Dowling, D. Meadows, T. Ayala, J. Marshall, S. Minshall, N. Greenberg, E. Thattassery, M. L. Fisher, et al. Letter Regarding Article by Wang et al, "Nesiritide Does Not Improve Renal Function in Patients With Chronic Heart Failure and Worsening Serum Creatinine" * Response Circulation, April 12, 2005; 111(14): e182 - e183. [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Burnett Nesiritide: new hope for acute heart failure syndromes? Eur. Heart J. Suppl., April 1, 2005; 7(suppl_B): B25 - B30. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Wang, T. C. Dowling, D. Meadows, T. Ayala, J. Marshall, S. Minshall, N. Greenberg, E. Thattassery, M. L. Fisher, K. Rao, et al. Nesiritide Does Not Improve Renal Function in Patients With Chronic Heart Failure and Worsening Serum Creatinine Circulation, September 21, 2004; 110(12): 1620 - 1625. [Abstract] [Full Text] [PDF]
|
|